On May 14, 2026, MetaVia, Inc. (MTVA) announced financial results for the first quarter of 2026 and provided a business update. In April 2026, the company dosed the first patient in the Phase 1 Part 3 trial of DA-1726, a dual oxyntomodulin analog that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist. This will be a 16-week titration study to evaluate 48 mg (1-step) and 64 mg (2-step) DA-1726 in obese but otherwise healthy adults. We anticipate topline results from the study in the fourth quarter of 2026. The company also announced multiple upcoming scientific presentations: On May 27, 2026 MetaVia will present a late-breaking poster on DA-1726 at the EASL Congress 2026 and on June 7, 2026 the company will present a poster at ADA 2026 on DA-1726 and two posters on vanoglipel, a novel G-protein-coupled receptor 119 (GPR119) agonist.
